Clinical trial
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
NCT00115765 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00115765 |
|---|---|
| Title | PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study |
| Official title | PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy, Bevacizumab |
| Enrollment | 1,053 |
| Start date | Jun 1, 2005 |
| Primary completion | May 31, 2007 |
| Completion | May 1, 2009 |
| First posted | Jun 27, 2005 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: